FDA Approves Velcade
FDA Approves Velcade (bortezomib) for Multiple MyelomaVelcade is an antineoplastic agent indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
Posted: May 2003
- FDA Approves Subcutaneous Administration of Velcade In All Approved Indications - January 24, 2012
- FDA Approves Addition of Sustained Overall Survival Benefit to Label for Velcade (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma - January 5, 2010
- FDA Approves Velcade (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma - June 23, 2008
- FDA Expands Velcade (Bortezomib) for Injection Label for Patients with Multiple Myeloma - October 15, 2007